Are there upcoming catalyst events (e.g., FDA decisions, conference presentations) that could move the stock?

Catalyst Outlook

The press release only covers Leap Therapeutics’ Q2‑2025 earnings and board activity; it does not name any specific upcoming FDA meetings, trial read‑outs, or conference presentations. In the biotech space, however, a quarterly results filing often precedes a series of near‑term catalysts that can drive the stock:

1. FDA & Regulatory Milestones – Leap’s pipeline is centered on targeted and immuno‑oncology programs. The next logical regulatory events are the upcoming FDA End‑of‑Phase‑2 (EOP2) meetings for its lead candidates, which are typically scheduled within 30‑45 days after a data‑generating trial. If any of these programs are slated for a Biology‑Based Licensing Agreement (BLA) submission later in 2025, the FDA’s PDUFA date will become a key price driver.

2. Data‑Driven Catalysts – The company is likely to present interim or topline data at the ASCO (June 2025) and AACR (April 2025) meetings. Even if the exact abstracts have not been disclosed yet, analysts and investors will watch for any “data‑driven” updates that Leap hints at in its earnings call transcript or investor deck. Historically, such presentations generate 10‑20 % price moves for comparable oncology‑focused peers.

Trading Implications

• Short‑term: Expect the stock to trade in a relatively tight range until the next regulatory or conference date is confirmed. The current earnings beat (sentiment score 10) may have already priced in near‑term optimism, so a breakout to the upside will likely require a positive FDA decision or compelling data release. Conversely, a sell‑off on a missed regulatory timeline could be swift, given the sector’s sensitivity to trial progress.
• Actionable: Monitor Leap’s investor‑relations channel for any filings of upcoming trial milestones (e.g., IND, IND‑NDA, or BLA filings) and watch for conference abstract releases in the next 4‑6 weeks. Positionally, a tight‑range, low‑volatility approach (e.g., selling premium‑straddles) can capture the “wait‑for‑catalyst” premium, while keeping a modest long‑biased stop‑loss just below the recent support level (≈ $1.85) to protect against a sudden negative regulatory update.